NCT00432458View on ClinicalTrials.gov

Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma

PHASE3CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

June 30, 2011

Study Completion Date

April 30, 2012

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
DRUG

Thalidomide

200 mg orally on days 1-28 of 28 day cycle

DRUG

zoledronic acid

4 mg\^2 by IV on day 1 every 84 days for 1 year and once per year thereafter

Trial Locations (4)

10065

Memorial Sloan-Kettering Cancer Center, New York

32224

Mayo Clinic - Jacksonville, Jacksonville

55905

Mayo Clinic Cancer Center, Rochester

85259-5499

Mayo Clinic Scottsdale, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT00432458 - Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma | Biotech Hunter | Biotech Hunter